VWM
STML

Vigilare Wealth Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Vigilare Wealth Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,000
Closed -$75K – 168
2019
Q4 		$75K Buy
+11,000
New +$109K 0.05% 147

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Vigilare Wealth Management's STML Position: Q1 2020 in Review

Vigilare Wealth Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 11,000 shares — an estimated $75K sold.

Vigilare Wealth Management first reported a position in STML in Q4 2019 and held it in 1 quarter. The position peaked at $75K in Q4 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • Vigilare Wealth Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Vigilare Wealth Management sold 11,000 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $75K.
  • Vigilare Wealth Management first reported a position in Stemline Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Vigilare Wealth Management's Stemline Therapeutics, Inc. position peaked at $75K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Vigilare Wealth Management's 13F filing for Q1 2020, filed 4 May 2020.